NCT05422781View on ClinicalTrials.gov

Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 13, 2022

Primary Completion Date

June 27, 2023

Study Completion Date

June 27, 2023

Conditions
Merkel Cell Carcinoma
Interventions
DRUG

ITI-3000

ITI-3000 is a DNA vaccine (L-H LT S220A) which contains sequences for both LAMP1 and LTS220A, the truncated form of the LT antigen of MCPyV with a detoxifying serine to alanine mutation at position 220

Trial Locations (1)

98109

University of Washington/Seattle Cancer Care Alliance, Seattle

Sponsors
All Listed Sponsors
lead

Immunomic Therapeutics, Inc.

INDUSTRY

NCT05422781 - Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC) | Biotech Hunter | Biotech Hunter